FDA grants historic approval to Alzheimer’s drug designed to slow cognitive decline
The landmark decision has been eagerly awaited by millions but will be hotly contested by some experts doubt the drug’s effectiveness.
Read The StoryBiotech
Inside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts
